High-quality dividend stocks are normally a great addition to any portfolio regardless of market conditions. However, this exceedingly risk-averse market has punished even elite dividend-paying stocks for relatively minor setbacks. 

Big pharma stalwart (NYSE: PFE) is a prime example. The drugmaker's shares have fallen by nearly 24% this year due largely to declining demand for the COVID-19 vaccine Comirnaty and the anti-viral treatment Paxlovid.

Upcoming patent losses haven't helped matters, either. Over the course of 2025 to 2030, Pfizer is expected to lose market exclusivity for the blood thinner Eliquis, kidney cancer drug Inlyta, breast cancer treatment Ibrance, anti-inflammatory medicine Xeljanz, prostate cancer therapy Xtandi, and cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis medicine Vyndaqel/Vyndamax. 

Continue reading

Source Fool.com